TargeGen

company

About

TargeGen, Inc., a vascular biology-focused biopharmaceutical company, discovers and develops small molecule kinase inhibitors that target.

  • 11 - 50

Details

Last Funding Type
Series B
Last Funding Money Raised
$30M
Industries
Biopharma,Biotechnology,Health Care
Founded date
Jan 1, 2002
Number Of Employee
11 - 50
Operating Status
Active

TargeGen, Inc., a vascular biology-focused biopharmaceutical company, discovers and develops small molecule kinase inhibitors that target vascular leakage (edema), vascular proliferation (angiogenesis), and inflammation. The company offers its products for the treatment of human diseases, such as heart attack, cancer, and eye diseases; vascular leakage, edema, and the unwanted growth of new blood vessels; pleural effusions, arthritis, pulmonary edema, transplant ischemia, ARDS, brain inflammation, hypovolemia (acute blood loss) CNS disorders, and other serious medical conditions. It serves macular degeneration, diabetic macular edema, and diabetic retinopathy markets.

The company was founded in 2002 and is based in San Diego, California. It was acquired by [Sanofi Aventis](/organization/sanofi-aventis-2) in 2010.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$70M
TargeGen has raised a total of $70M in funding over 2 rounds. Their latest funding was raised on Jul 12, 2007 from a Series D round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jul 12, 2007 Series D $40M 2 Innovis Investments Detail
Jan 15, 2004 Series B $30M 1 CDP Capital Technology Ventures Detail

Investors

Number of Lead Investors
Number of Investors
2
2
TargeGen is funded by 2 investors. Innovis Investments and CDP Capital Technology Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
Innovis Investments Yes Series D
CDP Capital Technology Ventures Series D